LexaGene Revenue and Competitors

Beverly, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • LexaGene's estimated annual revenue is currently $775k per year.(i)
  • LexaGene's estimated revenue per employee is $77,500

Employee Data

  • LexaGene has 10 Employees.(i)
  • LexaGene grew their employee count by -9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

LexaGene (OTCQB:LXXGF - TSX.V:LXG) is a molecular diagnostics company developing an open-access, fully automated system for rapid and sensitive pathogen detection. MiQLab is PCR-based and can detect up to 27 targets at once for testing in human clinical and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets that need critical answers in less time.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$775k

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

LexaGene's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
VP Application and BioinformaticsReveal Email/Phone
3
DirectorReveal Email/Phone
4
DirectorReveal Email/Phone
5
ScientistReveal Email/Phone
6
Sales ManagerReveal Email/Phone

LexaGene News

2022-04-20 - LexaGene has a huge upside, says iA Capital

LexaGene CEO and founder Dr. Jack Regan said the purchase could be the start of a “wave of adoption” of MiQLab. “Testing in the veterinary...

2022-04-19 - LexaGene Announces Multi-System Purchase from a ...

LexaGene Announces Multi-System Purchase from a Corporate Veterinary Reference Laboratory. April 25, 2022 08:45 ET | Source: LexaGene Holdings Inc LexaGene...

2022-03-22 - LexaGene Announces Advancements to its Sample ...

LexaGene's MiQLab® System is designed to process liquid samples from companion animals used in the diagnosis of infections such as urinary...

2021-09-07 - LexaGene : Files Preliminary Short Form Base Shelf Prospectus

BEVERLY, Mass. - September 3, 2021 - LexaGene Holdings, Inc. ('the Company'), (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announces that it has filed and received a receipt for a preliminary short form base she ...

2021-06-29 - LexaGene : Announces Fourth Quarter and Full-Year End February 28, 2021 Financial Results

BEVERLY, Mass. USA - June 29, 2021 -LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the 'Company'), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that the Company filed their Annual Information Form and its financial results ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M100%N/A
#2
$1.7M110%N/A
#3
$1.7M1110%N/A
#4
$0.9M1122%N/A
#5
$1.7M11-8%N/A